Safety and efficacy of commonly used antiemetics

Bibliography

• Kranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2002;46(3):238-44
   PubMed Web of Science ®Google Scholar
• Eberhart LH, Seeling W, Bopp TI, et al. Dimenhydrinate for prevention of post-operative nausea and vomiting in female in-patients. Eur J Anaesthesiol 1999;16(5):284-9
   PubMed Web of Science ®Google Scholar
• Kothari SN, Boyd WC, Bottcher ML, Lambert PJ. Antiemetic efficacy of prophylactic dimenhydrinate (Dramamine) vs ondansetron (Zofran): a randomized, prospective trial inpatients undergoing laparoscopic cholecystectomy. Surg Endosc 2000;14(10):926-9
   PubMed Web of Science ®Google Scholar
• Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Br J Anaesth 2003;90(5):665-70
   PubMed Web of Science ®Google Scholar
• Perwitasari DA, Gelderblom H, Atthobari J, et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 2011;33(1):33-43
   PubMed Web of Science ®Google Scholar
• Le TP, Gan TJ. Update on the management of postoperative nausea and vomiting and postdischarge nausea and vomiting in ambulatory surgery. Anesthesiol Clin 2010;28(2):225-49
   PubMedGoogle Scholar
• Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging 2011;6:243-59
   PubMed Web of Science ®Google Scholar
• Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002;113(Suppl 9A):38s-46s
   PubMed Web of Science ®Google Scholar
• Kimura K, Rusch D, Strasser C, et al. Influence of histamine release on postoperative vomiting (POV) following gynaecological laparoscopic surgery. Inflamm Res 2004;53(Suppl 2):S148-53
   PubMedGoogle Scholar
• Lin TF, Yeh YC, Yen YH, et al. Antiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous patient-controlled analgesia. Br J Anaesth 2005;94(6):835-9
   PubMed Web of Science ®Google Scholar
• del Cuvillo A, Mullol J, Bartra J, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006;16(Suppl 1):3-12
   PubMedGoogle Scholar
• Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996;36:233-52
   PubMed Web of Science ®Google Scholar
• Freedman SB, Fuchs S. Antiemetic therapy in pediatric emergency departments. Pediatr Emerg Care 2004;20(9):625-33. quiz 633-625
   PubMed Web of Science ®Google Scholar
• Cross MB, Warner K, Young K, Weiland AJ. Peripheral sympathectomy as a novel treatment option for distal digital necrosis following parenteral administration of promethazine. HSS J 2012;8(3):309-12
   PubMedGoogle Scholar
• Richelson E. Pharmacology of neuroleptics in use in the United States. J Clin Psychiatry 1985;46(8 Pt 2):8-14
   PubMed Web of Science ®Google Scholar
• Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007;105(6):1615-28
   PubMed Web of Science ®Google Scholar
• Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014;118(1):85-113
   PubMed Web of Science ®Google Scholar
• Schnabel A, Eberhart LH, Muellenbach R, et al. Efficacy of perphenazine to prevent postoperative nausea and vomiting: a quantitative systematic review. Eur J Anaesthesiol 2010;27(12):1044-51
   PubMed Web of Science ®Google Scholar
• Roila F, Feyer P, Maranzano E, et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 2005;13(2):129-31
   PubMed Web of Science ®Google Scholar
• Graham-Pole J, Weare J, Engel S, et al. Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin Oncol 1986;4(7):1110-13
   PubMed Web of Science ®Google Scholar
• Khalil S, Philbrook L, Rabb M, et al. Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery. J Clin Anesth 1999;11(7):596-600
   PubMed Web of Science ®Google Scholar
• Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Arch Intern Med 1998;158(19):2124-8
   PubMed Web of Science ®Google Scholar
• Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care 2010;27(3):219-25
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer 1998;83(6):1214-23
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993;329(24):1790-6
   PubMed Web of Science ®Google Scholar
• Yeung PK, Hubbard JW, Korchinski ED, Midha KK. Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 1993;45(6):563-9
   PubMed Web of Science ®Google Scholar
• Jordan K, Roila F, Molassiotis A, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer 2011;19(Suppl 1):S37-42
   PubMedGoogle Scholar
• Drotts DL, Vinson DR. Prochlorperazine induces akathisia in emergency patients. Ann Emerg Med 1999;34(4 Pt 1):469-75
   PubMed Web of Science ®Google Scholar
• Vinson DR, Drotts DL. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 2001;37(2):125-31
   PubMed Web of Science ®Google Scholar
• Musselman ME, Browning LA, Parker DJr, Saely S. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. Ann Pharmacother 2011;45(11):e61
   PubMedGoogle Scholar
• Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23(Suppl 1):27-41
   PubMed Web of Science ®Google Scholar
• Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007;21(10):813-33
   PubMed Web of Science ®Google Scholar
• Kovac AL. Update on the management of postoperative nausea and vomiting. Drugs 2013;73(14):1525-47
   PubMed Web of Science ®Google Scholar
• Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010;39(3):330-6
   PubMed Web of Science ®Google Scholar
• Wickham R. Evolving treatment paradigms for chemotherapy-induced nausea and vomiting. Cancer Contr 2012;19(2 Suppl):3-9
   PubMed Web of Science ®Google Scholar
• Henzi I, Walder B, Tramer MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000;90(1):186-94
   PubMed Web of Science ®Google Scholar
• Karanicolas PJ, Smith SE, Kanbur B, et al. The impact of prophylactic dexamethasone on nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis. Ann Surg 2008;248(5):751-62
   PubMed Web of Science ®Google Scholar
• Chen MS, Hong CL, Chung HS, et al. Dexamethasone effectively reduces postoperative nausea and vomiting in a general surgical adult patient population. Chang Gung Med J 2006;29(2):175-81
   PubMedGoogle Scholar
• Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg 2000;91(1):136-9
   PubMed Web of Science ®Google Scholar
• Chu CC, Hsing CH, Shieh JP, et al. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol 2014;722:48-54
   PubMed Web of Science ®Google Scholar
• Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20(12):2805-11
   PubMed Web of Science ®Google Scholar
• Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 2014;722:197-202
   PubMed Web of Science ®Google Scholar
• Eberhart LH, Seeling W, Ulrich B, et al. Dimenhydrinate and metoclopramide alone or in combination for prophylaxis of PONV. Can J Anaesth 2000;47(8):780-5
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Habib AS. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Br J Anaesth 2012;108(3):374-83
   PubMed Web of Science ®Google Scholar
• Zaki NM, Awad GA, Mortada ND, Abd Elhady SS. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 2007;32(4–5):296-307
   PubMed Web of Science ®Google Scholar
• Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21(6):1655-63
   PubMed Web of Science ®Google Scholar
• van der Meer YG, Venhuizen WA, Heyland DK, van Zanten AR. Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients? Crit Care 2014;18(5):502
   PubMed Web of Science ®Google Scholar
• Camilleri M, Shin A. Lessons from pharmacogenetics and metoclopramide: toward the right dose of the right drug for the right patient. J Clin Gastroenterol 2012;46(6):437-9
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19(4):379-90
   PubMed Web of Science ®Google Scholar
• Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs 2008;23(5):292-9
   PubMedGoogle Scholar
• Webb D, Buss DC, Fifield R, et al. The plasma protein binding of metoclopramide in health and renal disease. Br J Clin Pharmacol 1986;21(3):334-6
   PubMed Web of Science ®Google Scholar
• Rowbotham DJ. Current management of postoperative nausea and vomiting. Br J Anaesth 1992;69(7 Suppl 1):46s-59s
   PubMedGoogle Scholar
• Jo YY, Kim YB, Yang MR, Chang YJ. Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit -A case report. Korean J Anesthesiol 2012;63(3):274-6
   PubMedGoogle Scholar
• Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002;36(1):67-71
   PubMed Web of Science ®Google Scholar
• Cohen Y, Glantz L, Ezri T, Geva D. Metoclopramide induced akathisia during cesarean section. Int J Obstet Anesth 2000;9(2):137-9
   PubMed Web of Science ®Google Scholar
• Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry 2005;17(3):137-40
   PubMedGoogle Scholar
• Altorjay A, Melson T, Chinachoit T, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg (Chicago, Ill: 1960) 2011;146(2):201-6
   PubMed Web of Science ®Google Scholar
• Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997;17(3):531-7
   PubMed Web of Science ®Google Scholar
• Meyer RJ. FDA “black box” labeling. Ann Emerg Med 2003;41(4):559-60
   PubMed Web of Science ®Google Scholar
• Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003;41(4):546-58
   PubMed Web of Science ®Google Scholar
• Habib AS, Gan TJ. Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel? Anesth Analg 2008;106(5):1343-5
   PubMed Web of Science ®Google Scholar
• Fortney JT, Gan TJ, Graczyk S, et al. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg 1998;86(4):731-8
   PubMed Web of Science ®Google Scholar
• HALDOL brand of haloperidol injection (for immediate release) perscribing information. In
   Google Scholar
• Droperiddol:prescribing information. In
   Google Scholar
• Zivkovic M, Mihaljevic-Peles A, Bozina N, et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 2013;33(5):593-9
   PubMed Web of Science ®Google Scholar
• Chu CC, Shieh JP, Tzeng JI, et al. The prophylactic effect of haloperidol plus dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy. Anesth Analg 2008;106(5):1402-6. table of contents
   PubMed Web of Science ®Google Scholar
• Braude D, Soliz T, Crandall C, et al. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. Am J Emerg Med 2006;24(2):177-82
   PubMed Web of Science ®Google Scholar
• Benevides ML, Oliveira SS, de Aguilar-Nascimento JE. The combination of haloperidol, dexamethasone, and ondansetron for prevention of postoperative nausea and vomiting in laparoscopic sleeve gastrectomy: a randomized double-blind trial. Obes Surg 2013;23(9):1389-96
   PubMed Web of Science ®Google Scholar
• Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database Syst Rev 2009(2):Cd006271
   PubMed Web of Science ®Google Scholar
• Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 2009;69(5):515-33
   PubMed Web of Science ®Google Scholar
• Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002;23(6):526-32
   PubMed Web of Science ®Google Scholar
• Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65(4):464-70
   PubMed Web of Science ®Google Scholar
• Transderm Scop (scopolamineransdermal system patch:perscribing information. In
   Google Scholar
• Bailey PL, Streisand JB, Pace NL, et al. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Anesthesiology 1990;72(6):977-80
   PubMed Web of Science ®Google Scholar
• Sah N, Ramesh V, Kaul B, et al. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. J Clin Anesth 2009;21(4):249-52
   PubMed Web of Science ®Google Scholar
• Pergolizzi JVJr, Philip BK, Leslie JB, et al. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesthesia 2012;24(4):334-45
   PubMed Web of Science ®Google Scholar
• Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005;27(5):655-65
   PubMed Web of Science ®Google Scholar
• Gan TJ, Sinha AC, Kovac AL, et al. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting. Anesth Analg 2009;108(5):1498-504
   PubMed Web of Science ®Google Scholar
• van der Vorst MJ, Neefjes EC, Konings IR, Verheul HM. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Support Care Cancer 2015;23(8):2499-506
   PubMed Web of Science ®Google Scholar
• EMEND (aprepitant) capsules, for oral use: perscribing information. In
   Google Scholar
• EMEND (fosaprepitant dimeglumine) for injection, for intravenous use, perscribing information. In
   Google Scholar
• Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69(13):1853-78
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007;99(2):202-11
   PubMed Web of Science ®Google Scholar
• Bauters TG, Verlooy J, Robays H, et al. Emesis control by aprepitant in children and adolescents with chemotherapy. Int J Clin Pharm 2013;35(6):1021-4
   PubMedGoogle Scholar
• Huskey SE, Dean BJ, Bakhtiar R, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos 2003;31(6):785-91
   PubMed Web of Science ®Google Scholar
• Bhandari PR. Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting. J Adv Pharm Technol Res 2012;3(4):202-9
   PubMedGoogle Scholar
• Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52(5):773-94
   PubMed Web of Science ®Google Scholar
• Parker L, Rock E, Limebeer C. Regulation of Nausea and Vomiting by Cannabinoids. Br J Pharmacol. 2011;163(7):1411-22
   PubMed Web of Science ®Google Scholar
• Amar B. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006;105(1–2):1-25
   PubMed Web of Science ®Google Scholar
• Sharma P, Murthy P, Bharath MM. Chemistry, Metabolism and Toxicology of Cannabis: Clinical Implications. Iran J Psychiatry 2012;7(4):149-56
   PubMedGoogle Scholar
• Tramer M, Carroll D, Campbell F, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323(7303):16-21
   PubMed Web of Science ®Google Scholar
• Yang LP, Scott LJ. Palonosetron: in the prevention of nausea and vomiting. Drugs 2009;69(16):2257-78
   PubMed Web of Science ®Google Scholar
• Bajwa SS, Bajwa SK, Kaur J, et al. Palonosetron: A novel approach to control postoperative nausea and vomiting in day care surgery. Saudi J Anaesth 2011;5(1):19-24
   PubMedGoogle Scholar
• George E, Hornuss C, Apfel CC. Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting. Curr Opin Anaesthesiol 2010;23(6):714-21
   PubMed Web of Science ®Google Scholar
• Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991;41(4):574-95
   PubMed Web of Science ®Google Scholar
• Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf 2003;26(4):227-59
   PubMed Web of Science ®Google Scholar
• Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23(11):1225-30
   PubMed Web of Science ®Google Scholar
• Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther 2010;17(5):476-86
   PubMed Web of Science ®Google Scholar
• Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993;46(5):925-43
   PubMed Web of Science ®Google Scholar
• Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000;59(6):1297-315
   PubMed Web of Science ®Google Scholar
• Yang LPH, Scott LJ. Palonosetron: In the prevention of nausea and vomiting. Drugs 2009;69(16):2257-78
   PubMed Web of Science ®Google Scholar
• Wallenborn J, Kranke P. Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting. Clinical Medicine Insights: Therapeutics 2010;2:387-99
   Google Scholar
• Kovac AL. Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists. J Clin Anesth 2006;18(4):304-18
   PubMed Web of Science ®Google Scholar
• Kovac AL. Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists. J Clin Anesth 2006;18(4):304-18
   PubMed Web of Science ®Google Scholar
• Cohen IT. Ondansetron for postoperative nausea and vomiting. Therapy 2006;3(5):571-8
   Google Scholar
• Sorbe B, Berglind AM. Tropisetron, a new 5-HT3-receptor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhoea. Drugs 1992;43(Suppl 3):33-9
   PubMedGoogle Scholar
• Kuryshev YA, Brown AM, Wang L, et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000;295(2):614-20
   PubMed Web of Science ®Google Scholar
• Ward A, Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985;30(2):127-44
   PubMed Web of Science ®Google Scholar
• Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 2008;4(1):99-107
   PubMedGoogle Scholar